Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance on long-context tasks. RLMs use a programming environment to recursively ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling ...

Why Recursion Pharmaceuticals Is On Investors’ Radar Recursion Pharmaceuticals (RXRX) has been drawing attention after recent ...

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Blockchain networks face a quiet but serious problem that grows over time. As transactions pile up, nodes must store more ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.70, marking a -3.29% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...

AI superintelligence could be more dangerous than nuclear weapons, but importantly, nobody has built it yet. We can still ...